SG11202105137RA - Application of chidamide in combination with r-chop, and drug combination - Google Patents

Application of chidamide in combination with r-chop, and drug combination

Info

Publication number
SG11202105137RA
SG11202105137RA SG11202105137RA SG11202105137RA SG11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA
Authority
SG
Singapore
Prior art keywords
combination
chidamide
chop
application
drug
Prior art date
Application number
SG11202105137RA
Inventor
Xianping Lu
Weili Zhao
Xin Fu
Pengpeng Xu
Ting Liu
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Rui Jin Hospital Affiliated To Shanghai Jiao Tong Univ School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd, Rui Jin Hospital Affiliated To Shanghai Jiao Tong Univ School Of Medicine filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of SG11202105137RA publication Critical patent/SG11202105137RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202105137RA 2018-11-20 2019-11-18 Application of chidamide in combination with r-chop, and drug combination SG11202105137RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811394614 2018-11-20
PCT/CN2019/119170 WO2020103788A1 (en) 2018-11-20 2019-11-18 Application of chidamide in combination with r-chop, and drug combination

Publications (1)

Publication Number Publication Date
SG11202105137RA true SG11202105137RA (en) 2021-06-29

Family

ID=70741744

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105137RA SG11202105137RA (en) 2018-11-20 2019-11-18 Application of chidamide in combination with r-chop, and drug combination

Country Status (12)

Country Link
US (1) US20220016147A1 (en)
EP (1) EP3884943A4 (en)
JP (1) JP7489397B2 (en)
KR (1) KR20210104059A (en)
CN (2) CN117797149A (en)
AU (1) AU2019385373A1 (en)
BR (1) BR112021009627A2 (en)
CA (1) CA3120207A1 (en)
PH (1) PH12021551138A1 (en)
SG (1) SG11202105137RA (en)
TW (1) TWI768263B (en)
WO (1) WO2020103788A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113813268A (en) * 2020-06-18 2021-12-21 苏州亚盛药业有限公司 Combination comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL inhibitor and uses thereof
CN112274509B (en) * 2020-12-02 2022-04-26 四川大学华西医院 Application of xidabenamine and BCL2 inhibitor in double-expression B cell lymphoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413826A (en) * 2003-08-26 2006-10-24 Aton Pharma Inc process of treating cancer with hdac inhibitors
CN101470112A (en) * 2007-12-28 2009-07-01 上海交通大学医学院附属瑞金医院 Molecule mark for diffuse large b-cell lymphoma treating guide and prognosis judgment
TWI808055B (en) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
MX2019000864A (en) 2016-07-20 2019-06-03 Univ Columbia Histone acetyltransferase activators and compositions and uses thereof.
CN107157978B (en) * 2017-05-24 2021-06-18 中国药科大学 Medicine and composition for treating EBV + DLBCL and DLBCL
CN108743947B (en) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 Pharmaceutical composition for treating B cell lymphoma

Also Published As

Publication number Publication date
JP2022511126A (en) 2022-01-28
TWI768263B (en) 2022-06-21
JP7489397B2 (en) 2024-05-23
CN117797149A (en) 2024-04-02
BR112021009627A2 (en) 2021-08-10
PH12021551138A1 (en) 2022-02-21
EP3884943A4 (en) 2022-07-06
CN111195249B (en) 2023-11-28
TW202033194A (en) 2020-09-16
KR20210104059A (en) 2021-08-24
WO2020103788A1 (en) 2020-05-28
CN111195249A (en) 2020-05-26
EP3884943A1 (en) 2021-09-29
CA3120207A1 (en) 2020-05-28
AU2019385373A1 (en) 2021-06-24
US20220016147A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
IL279015A (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
SG11202105173VA (en) Modified cell expressing therapeutic agent and uses thereof
SG11202001647UA (en) Conjugate of vegf-grab protein and drug, and use thereof
GB201604213D0 (en) Drug combination and its use in therapy
PT3615035T (en) Use of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathies
IL273339A (en) Griseofulvin compound and pharmaceutical use thereof
DK3275453T3 (en) PHARMACEUTICAL COMPOSITION WITH SILIBININE AND VE
GB201820659D0 (en) Novel compostions and their use in therapy
PL3658122T3 (en) Pharmaceutical composition comprising sacubitril and valsartan
DK3334760T3 (en) Coated and uncoated antibody cysteines, and their use in antibody-drug conjugation
EP3630124A4 (en) Synthetic composition comprising oligosaccharides and its use in medical treatment.
SG11202105137RA (en) Application of chidamide in combination with r-chop, and drug combination
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
SG11202004529XA (en) Transformed human cell and use thereof
IL282526A (en) Azaindazole-5 derivatives and their use
SG11201906132UA (en) Insoluble complex or solvate thereof, pharmaceutical composition and use thereof
EP3696178A4 (en) Heterocyclic compound and application thereof in medicine
EP3615064A4 (en) Enriched cellular compositions and therapeutic use
IL282142A (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
EP4069233A4 (en) Pharmaceutical combination and use thereof
GB201519644D0 (en) Therapy and pharmaceutical composition
PL3212280T3 (en) Tinnitus fitting in ci and abi patients
PL3630188T3 (en) A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
EP3718543A4 (en) Pharmaceutical composition and use thereof